and thereby promoting tumor growth. The anti-tumor activity of effector T cells can be therapeutically unleashed, and is now being exploited for the treatment of various types of human cancer. However, the immune suppressive function of Treg cells remains a major hurdle to broader effectiveness of tumor immunotherapy. In this article, we reported that the deletion of Bcl6 specifically in Treg cells led to stunted tumor growth, which was caused by impaired Treg cell responses. Notably, Bcl6 is essential in maintaining the lineage stability of Treg cells in tumor microenvironment. Meanwhile, we found that the absence of follicular regulatory T (Tfr) cells, which is a result of Bcl6 deletion in Treg cells, was dispensable for tumor control. Importantly, the increased Bcl6 expression in Treg cells is associated with poor prognosis of human colorectal cancer. Furthermore, Bcl6 deletion in Treg cells exhibits synergistic effects with immune checkpoint blockade therapy. Collectively, these results indicate that Bcl6 actively participates in regulating Treg cell immune responses during tumorigenesis and can be exploited as a therapeutic target of anti-tumor immunity.
Adoptive transfer studies have shown that cTreg cells could convert into more highly proliferative eTreg cells in response to tissue self-antigens. 13 Notably, eTreg cells have also been observed in increased numbers within diverse experimental mouse tumors and human cancers which suggest the involvement of Treg cells in anti-tumor immunity. 14, 15 The depletion of Treg cells, which results in tumor rejection and retardation of tumor growth, has been reported in mouse models. [16] [17] [18] For several types of human cancers, including melanoma, non-smallcell lung, gastric and ovarian cancers, Treg cells account for 10-50% of tumor infiltrated CD4 T cells compared with 2-5% of CD4 T cells in the peripheral blood of healthy individuals. 19, 20 Furthermore, a relatively high infiltration abundance of Treg cells versus non-Treg cells in TME is associated with poor prognosis in cancer patients. 21 Using single cell sequencing, it has been found that the majority of tumor infiltrating Treg cells are uniformly highly activated comparing with those in periphery tissues 22 , with lower level of CD45RA and CCR7 expression, and highly enriched for a range of co-stimulatory molecules such as CD27, ICOS, OX40, 41BB, GITR, and co-inhibitory molecules such as CTLA4, PD1, LAG3, and TIGIT. Remarkably, a number of cytokines and chemokine receptor genes, most notably CCR8, were upregulated in tumor-resident Treg cells in comparison to normal tissue-resident ones. 23 These information supports the notion that tumor infiltrating Treg cells hold a distinct transcriptional profiling however, the underlying mechanisms regulating Treg cells within TME still remain obscure. 22 The transcription factor B cell lymphoma 6 (Bcl6) is intensively investigated during the development of several types of T cell subpopulations and its fine-tuned expression is modulated by a net of cytokines (e.g., IL6, IL12, IFNγ, type I IFN signaling, TGFβ, and TNFα) in a variety of cell types and repressed by IL2-STAT5 signaling. [24] [25] [26] [27] It controls T follicular helper (Tfh) cell development and is expressed by Foxp3 + T follicular regulatory (Tfr) cells. [28] [29] [30] The specific deletion of Bcl6 in Treg cells in mouse models do not result in spontaneous inflammatory disease, however, it did enhance Th2mediated airway inflammation following immunization. 31 Bcl6-deficient Treg cells express higher level of GATA3 when compared with WT (wild-type) Treg cells, and it seems that Bcl6 controls the Th2 inflammatory activity of Treg cells by repressing GATA3. 32 We revealed that together with TCF1, Bcl6 is critical in transducing mTORC1 signaling in regulating Tfr differentiation during protein immunization or viral infection. 33 However, whether Bcl6 possesses a role in regulating Treg cells during tumorigenesis has not been explored.
In this study, we found that Bcl6 expression is enhanced in Treg cells under TME, indicating that Bcl6 potentially serves to regulating the suppressive function of Treg cells on Teff cells in TME. Accordingly, depleting Bcl6 in Treg cells enhanced anti-tumor capability and retarded tumor progression. Moreover, this anti-tumor effect can synergize with anti-CTLA4 or anti-PD1 therapy, thus may serve as a therapeutic target to further improve the efficacy of immune checkpoint blockade responders.
Materials and methods

Mice
Bcl6-RFP (Bcl6 rfp/+ or Bcl6 rfp/rfp ) mice were generously provided by Dr. Xindong Liu (Southwest Hospital, Chongqing, China). Foxp3 DTR were generously provided by Dr. Hua Tang (Institute of Immunology, Shandong First Medical University, Jinan, China). CXCR5-GFP knock-in mice have been described previously. 34 Bcl6 fl/fl , Foxp3 YFP-Cre knock-in, Cxcr5 -/-, C57BL/6J (CD45.1 and CD45.2) mice were purchased from Jackson Laboratory. Bcl6 fl/fl mice were bred with Foxp3 YFP-Cre knock-in mice to generate Bcl6 fl/fl Foxp3 Cre mice. All these strains are C57BL/6 background. All the mice used were analyzed at 6-10 weeks of age, and both genders were included without randomization or "binding". Bone marrow (BM) chimeras were used after 8-10 weeks of reconstitution. LCMV virus (Armstrong strain) was provided by R. Ahmed (Emory University) and propagated in our laboratory as previously described. 35 And 2×10 5 plaque-forming units of this strain were used to establish acute infection in mice. For all the phenotypic analysis, at least 3 animals of each genotype with matched age and gender were analyzed. All mouse experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committees of the Third Military Medical University. This study was specifically reviewed and approved by the Laboratory Animal Welfare and Ethics Committee of the Third Military Medical University.
Tissue Preparation
Spleens were surgically removed with sterilized surgical equipment and crushed with the blunt of 1mL syringe on Petri dishes containing 3mL of red blood cell lysis buffer. The spleen mixtures were separately filtered through a 70μM filter into a 15mL conical centrifuge tube, centrifuged at 1800rpm for 6min at 4 . After wash, cell pellets were resuspended in 5mL of R2 media (RPMI (SIGMA Cat. RNBH7001) + 2% fetal bovine serum (FBS; gibco Cat. 10270-106)). Draining lymph nodes (dLNs) were extracted with sterilized surgical equipment and crushed between the frosted surfaces of superfrosted microscope slides into wells containing R2. Cell mixtures were then filtered through a 70μM filter into a 15mL conical centrifuge tube, centrifuged at 1800rpm for 6min at 4 . After wash, cell pellets were resuspended in 0.5mL of R2 media. Tumors were removed from mice with sterile surgical instruments, pictured and weighted then shredded with ophthalmic scissors. Tumor tissue mixtures were transferred into 15mL conical tubes and filled with collagenase digest media (R2+Collagenase).
B16-F10 Lung tumor tissue were treated with type2 collagenase (Sangon Biotech Cat. A004174-0001) and MC-38 solid tumor tissues were treated with type1 collagenase (Sangon Biotech Cat. A004194-0001). Samples were subsequently placed on a 37℃ shaker for 1 hour, then filtered through 100μM filters into 50mL conical tubes and washed with R2 before centrifugation. Tumor cells were fractionated 2000rpm for 30 min at 4℃ on a two-step gradient consisting 44% and 67% Percoll solutions (GE Cat. 17-0891-09). The T cell fraction was recovered from the inter-face between the 2 layers.
Flow Cytometry and Antibodies
Flow cytometry data were acquired with a FACSCantoⅡ (BD Biosciences) and were analyzed with FlowJo software (Tree Star). The antibodies and reagents used for flow cytometry staining are listed in Supplementary Table 1 . Surface staining was performed in PBS containing 2% BSA or FBS (w/v). Tfh cell staining has been described. 36 Staining of Bcl6, Bcl2, Tbet and Foxp3 were performed with the Foxp3/Transcription Factor Staining Buffer Set (00-5523; eBioscience). For in vivo incorporation of the thymidine analog BrdU, mice were given BrdU (1.5mg BrdU (5-bromodeoxyuridine) in 0.5ml PBS) intraperitoneally 3h before mice were sacrificed. BrdU in T cells was stained with a BrdU Flow Kit (552598; BD Biosciences) according to the manufacturer's instructions. For the detection of cytokine production, lymphocytes were stimulated for 5h in the presence of PMA (50ng/ml), ionomycin (1μg/ml), Golgi Plug, Golgi Stop, anti-CD107a and anti-CD107b antibodies (BD Bioscience).
Intracellular cytokine staining for CD107, granzyme B and Ki67 were performed with the Cytofix/Cytoperm Fixation/Permeabilization Kit (554714, BD Biosciences).
Adoptive Transfer and Generation of Bone Marrow Chimeras
A total of approximately 1×10 6 WT Treg cells mixed with KO Treg cells with the ratio of 1:1 were adoptively transferred into cyclophosphamide (CTX, Sigma) treated (single dose at 200mg/kg, 12-24 hours before T cell transfer) CD4 -/mice, which were inoculated with B16-F10 cells intravenously or MC-38 intraperitoneally on the following day. Bone marrow was collected from Foxp3 DTR and Cxcr5 -/mice. Approximately 5×10 6 cells of a 1:1 mixture of Foxp3 DTR and CXCR5 -/bone marrow cells were transferred intravenously into sub-lethally irradiated (two doses of 4.5 Gy each) CD4 -/recipients.
Recipient mice were reconstituted for 8-10 weeks before tumor transplantation. CD4 + CD25 + GITR + CXCR5and CD4 + CD25 + GITR + CXCR5 + T cells from WT or Bcl6 fl/fl Foxp3 Cre mice were sorted from tumor tissues or dLNs. CD8 + CD44 + T cells from WT mice were sorted from dLNs. 100,000 CD8 + Teffs were incubated with different numbers of CD4 + CD25 + GITR + CXCR5or CD4 + CD25 + GITR + CXCR5 + T cells from WT or Bcl6 fl/fl Foxp3 Cre mice at 37℃ for 72 hours and were assessed by flow cytometry.
Cell culture and In vitro suppression assay
Quantitative RT-PCR
For comparison of gene expression in Bcl6 -/-Treg cells and wild-type Treg cells both in naive state and tumor bearing state, Treg cells (CD4 + CD25 + GITR + ) were sorted from naive or tumor implanted mice and were subsequently lysed in TRIzol LS reagent (10296; Life Technologies). Total RNA was extracted and reverse-transcribed with a RevertAid H Minus First Strand cDNA Synthesis Kit (K1632; Thermo Scientific). The resulting cDNA was analyzed for the expression of various target genes with a QuantiTest SYBR Green PCR Kit (204143; Qiagen) and the corresponding primers on a CFX96 Touch Real-Time System (Bio-Rad) (Supplementary Table 2 ).
Analysis of TCGA data
The TCGA normalized RNA-seq data of human colorectal cancer patients were downloaded from https://genome-cancer.ucsc.edu/. None of the patients had any record of immunotherapy treatment. 352 patients with primary tumor were included into analysis. Samples/patients were split based on gene expression levels analyzed by receiver operating characteristic curve and grouped into Foxp3 lo (66.76%) and Foxp3 hi (33.24%). Foxp3 hi ones were further divided into Bcl6 lo (50.64%) and Bcl6 hi (49.36%) subpopulations for analysis. Survival curves were then generated and differences were evaluated by Log-rank test.
Statistical Analysis
Statistical analysis was conducted with Prism 7 software (GraphPad). An unpaired two-tailed t-test with 95% confidence interval was used to calculate P-values. For bone marrow and splenic chimera experiments, a paired two-tailed t-test with 95% confidence interval was used to calculate P values.
Tumor growth curves at different time points were plotted by two-way ANOVA with a Turkey post hoc test comparison among groups.
Results
The deficiency of Bcl6 in Treg cells leads to delayed tumor progression
To investigate the role of Bcl6 in Treg cells immune response during tumorigenesis, we first evaluated the expression pattern of Bcl6 in Treg cells in TME and tumor dLNs of wild-type (WT) mice subcutaneously implanted with B16-F10 melanoma cells (in situ model). Using flow cytometry analysis, we observed that tumor infiltrating Treg cells and tumor dLN derived Tregs cells expressed higher level of Bcl6 than Treg cells from spleens (Supplemental Figure 1a ). The enhanced expression of Bcl6 in the first two populations of Treg cells indicates an important but unsolved role of Bcl6 within TME. To this end, we crossed Bcl6 fl/fl mice with Foxp3 YFP-Cre (Foxp3 Cre ) mice to generate mice in which the Bcl6 alleles are conditionally deleted in Foxp3 + Treg cells (hereafter referred to as Bcl6 fl/fl Foxp3 Cre mice). Then we challenged these mice with B16-F10 melanoma cells or MC-38 cells.
We observed that tumor growth was significantly repressed in knockout (KO) mice when compared to that in WT mice of both models (Figure 1a , c). And this phenotype was further corroborated by decreased tumor weight at the endpoint of each experiment (Figure 1b, d ).
Next, we sought to investigate the role of Bcl6 during tumor metastasis. We challenged Bcl6 fl/fl Foxp3 Cre and WT mice with B16-F10 melanoma cells intravenously to generate lung metastasis model. Firstly, using real-time PCR, we confirmed the upregulation of Bcl6 transcripts in tumor infiltrating Treg cells when compared with dLNs derived Treg cells and CD44 -CD4 T cells (Supplemental Figure 1b ). And in order to continuously monitor tumor metastasis, we introduced the B-Luciferase B16-F10 cell line, which carries a luciferase-coding sequence in genome. At day 11 (D11) post tumor inoculation, we noted weaker fluorescent dots in KO mice with in-vivo imaging system (Figure 1e ), indicating less metastatic foci in KO group than in control group. Consistently, we also observed less metastatic foci in KO mice compared to WT mice at day 18 post tumor inoculation ( Figure 1f ). In line with this result, Bcl6 fl/fl Foxp3 Cre mice also demonstrated better survival rate when compared to WT counterparts ( Figure   1g ). Moreover, when proliferation-indicating dye labeled B16-F10 cells were intravenously transferred into WT and KO mice respectively, we harvested the same number of violet positive B16-F10 cells from lung tissues of both groups two hours later, indicating the comparable migration capacity of tumor cells within both groups. However, 20 hours later, a significant decrease in the number of pulmonary B16-F10 cells suggested that the lungs of KO mice represent a hostile environment for tumor cell engraftment (Figure 1h ). Consistently, we conducted in vitro suppression assay by co-culturing WT or Bcl6-deficient tumor infiltrating Treg cells with CFSE-labelled naive CD8 T cells that were followed by anti-CD3 and CD28 stimulation, and the results showed that Bcl6-deficient Treg cells exhibited impaired suppressive function compared with that of WT Treg cells (Figure 2g ). Contrarily, when isolating cells from naive mice, WT or Bcl6-deficient Treg cells exhibited comparable suppressive function (Figure 2g ).
The deficiency of Bcl6 impaired the suppressive capacity of Treg cells in TME
Collectively, these data indicated that the abrogation of Bcl6 in Treg cells severely dampened the suppressive function of Treg cells in a cell intrinsic manner in TME, without profoundly influencing the absolute number of Treg cells.
Tfr cells are dispensable for tumor control
It has been reported that Bcl6 participates in regulating the differentiation of follicular regulatory T cells (Tfr), 33 which is a subset of Treg cells endowed with the capacity to inhibit germinal center reaction. To test whether tumor repression in KO mice was contributed by compromised Tfr response, we first examined Tfr population within tumor using CXCR5 GFP reporter mice. 34 Notably, GFP + Foxp3 + CD4 + T cells were barely detected in tumor, while a substantial population of Tfr was observed in dLNs (Supplemental Figure 2d ), suggesting the absence of Tfr population in tumor mass.
Consistent with published data, 33 (Figure 3d ) and CD44 + CD8 + T cells (Figure 3e ). Thus, these data demonstrated that Tfr cells were dispensable for tumor control.
Bcl6 is essential in maintaining the lineage stability of Treg cells in TME
In order to illustrate the underlying mechanisms of Bcl6 in regulating Treg cell response during tumorigenesis, we sorted antigen experienced Treg, Th1 and Tfh cells as well as naive Treg cells from WT and KO mice at 16 days after tumor implantation to extract total RNA and conduct an array of quantitative real-time PCR (RT-qPCR) to profile the transcriptional signatures of the indicated subsets of CD4 T cells. Consistent with FACS data (shown in Figure 2f ), the deficiency of Bcl6 resulted in reduced expression of Foxp3 in Treg cells in tumor model ( Figure 4a ). However, it had no effects on Foxp3 expression in naive state (Figure 4b) , indicating that the identity of Bcl6-deficient Treg cells might be preferentially altered within TME. Accordingly, compared with WT counterparts, KO derived tumor infiltrating Treg cells upregulated the expression level of Gata3, which encodes the master transcriptional factor (TF) of Th2, as well as Th2 related cytokine IL4 (Figure 4c ). Meanwhile, the expression of Th17 related cytokine IL17 also increased in KO mice despite similar level of retinoic acid receptor-related orphan receptor (ROR)γt between WT and KO group (Figure 4d ). During naive state, however, KO Treg cells exhibited normal stability indicated by comparable level of Gata3, Il17
and Rorc expression compared with WT mice (Figure 4e ). These data suggested that the altered identity of Treg cells in KO mice was specifically confined to tumor micro-environment. Moreover, by analyzing Treg cells derived from different donors in spleen chimera mice (lung metastasis model), we further confirmed the enhanced expression of Tbet and GATA3 in KO Treg cells compared with WT ones in both tumor tissue ( Figure 4f ) and dLNs (Supplemental Figure 2c ). All together, these data suggested the important role of Bcl6 in maintaining the lineage stability of Treg cells during tumorigenesis.
Bcl6 expression in Treg cells may predict the prognosis of human colorectal cancer
Given that the deficiency of Bcl6 in Treg cells resulted in repressed tumor growth in mouse models, we further checked whether Bcl6 expression could be exploited as an indicator for the clinical prognosis of human cancer patients. Interestingly, analysis of the independent human colorectal cancer cohort from TCGA (The Cancer Genome Atlas) database demonstrated that patients with higher level of Bcl6 (in Foxp3 + CD4 + cells) showed significantly poorer overall survival compared to those with a lower level ( Figure 5a ). Moreover, the expression level of Bcl6 in Treg cells negatively correlates with the pathological grading of colorectal cancer, indicated by progressively increased proportion of Bcl6 hi Treg cells from pathological stage to stage (TNM stage) colorectal cancer patients (Figure 5b ).
Finally, we evaluated the synergetic effects of Bcl6 deletion with immune check point blockade (ICB).
Consistent with published data, [38] [39] [40] anti-CTLA4 or anti-PD1 alone significantly repressed tumor growth, which is comparable to that in KO group. Although Bcl6 deletion alone greatly improved the therapeutic efficacy, the combination of Bcl6 deletion and anti-CTLA4 or anti-PD1 did exhibit additional effects at delaying tumor growth ( Figure 5d -e), indicating that Bcl6 can be a potential therapeutic target combined with ICB in cancer immunotherapy.
Discussion
Treg cells readily infiltrate into the TME and dampen anti-tumor immune responses, thereby becoming a barrier to effective cancer immunotherapy. In the past few years, Bcl6 has emerged as a central regulator of Tfh cell differentiation. 35, 41, 42 However, the role of Bcl6 in Treg cells function has not been completely elucidated, particularly in terms of anti-tumor immune response. In this study, to specifically assess the role of Bcl6 in tumor infiltrating Treg cells, we challenged Bcl6 fl/fl Foxp3 Cre mice with tumor cells and found that tumor growth was retarded in effector Treg cells (TCF1 -LEF1 -CD62L -CD44 hi ). 43 Notably, Bcl6 was selectively enriched in activated Treg cells. 43 In naive state, Treg cells contain a large fraction of resting Treg subsets, while only a small proportion of Treg cells are active or effector subsets. In tumor microenvironment, however, the highly suppressive signatures of Treg cells suggest an enrichment of activated or effector Treg subsets. Thus, Bcl6 may have a more pronounced effect in Treg cells within tumors.
Treg cells function is highly orchestrated, such that specific transcription factors regulate the ability of
Treg cells to inhibit discrete types of T cell responses. It has been reported that T-bet uniquely controls the ability of Treg cells to suppress Th1 responses, 44 IRF4 regulates the ability of Treg cells to suppress
Th2 responses, 45 and Stat3 directs the ability of Treg cells to suppress Th17 responses. 46 Accordingly, Bcl6, which is the master regulator of Tfh cells, regulates the differentiation of Treg cells to Tfr and thus influence the ability of treg cells to control Tfh response. 33 In this study, we found Bcl6 can also regulate Treg cell's function in regulating the antitumor effects of other T cell lineages, which was shown in a Tfr independent pathway.
Bcl6 deletion significantly down regulate the expression of Foxp3 in tumor infiltrating Treg cells, which critically specifies the Treg lineage and maintains its functional program 47 . But how Bcl6 regulate Foxp3 expression and function of tumor infiltrating Treg cells remains unsolved in our study.
In Th cells, Bcl6 was reported to inhibit Th1, Th2, and Th17 development by suppressing Tbet, GATA3, and RORγt expression and activities. 29, 41, 48 Meanwhile, it was reported that Bcl6 represses GATA3 expression in Treg cells and thus prevents Treg cells from acquiring Th2 effector-like characteristics.
Consistently, we found an upregulation of Tbet, GATA3, and Th17 related cytokine (IL17) in KO Treg cells during tumorigenesis. However, whether Bcl6 uniquely targets these genes in Treg cells in this scenario requires further investigation.
Given the initial clinical successes achieved using PD1/PDL1 or CTLA4 antibody treatments in patients with cancer, the number of immunotherapy agents in clinical development is expanding rapidly with goals of improving the limited response rate and generating more durable responses. 49, 50 However, the clinical efficacy of ICBs is limited to only a small portion of patients, suggesting the importance to design new combinatory strategies. 51 Currently, Treg cell targeted anti-cancer therapy have been tested clinically and/or preclinically. Some of the direct strategies involve targeting of those molecules specifically expressed by Treg cells, such as CTLA4, GITR, CD25 or ICOS. Several Treg cell-targeted therapies are under investigation alone or in combination with ICBs. 1, 52, 53 Indeed, the anti-CTLA4 mAb ipilimumab can reinvigorate exhausted CD8 T cells while reportedly depleting Treg cells from the TME, which might contribute to the clinical benefits of this agent. [54] [55] [56] [57] Yet, one possible concern with Treg cell-targeted therapy is that systemic Treg cell depletion might considerably increase the risk of immune-related adverse events, such as autoimmunity owing to systemic disruption of immune tolerance. 1, 52 And several groups did observe an increased risk of colitis, rash and liver toxicity during the combined therapy of nivolumab with ipilimumab (an agent that can reportedly deplete or suppress Treg cells). 58, 59 Mogamulizumab has also been associated with the development of rash and liver toxicity. 60 For this reason, targeting Treg cells locally within the tumor could be a better approach that might avoid adverse events. In our study, we found that the induction of Bcl6 expression was strictly (a-c) Flow cytometry of splenic chimera mice (B16-F10, metastasis model). Splenocytes from WT and Bcl6 fl/fl Foxp3 Cre mice were collected and mixed with Treg cells in a ratio of 1:1, and were adoptively transferred (1×10 6 cells per mice) to CD4 -/recipients. On the following day, 1×10 6 B16-F10 cells were injected intravenously into recipient mice and mice were sacrificed at day 18 post tumor inoculation.
Quantification of Foxp3, CTLA4, CD25 and ICOS in Treg cells from tumor tissue (a) and dLNs (b). 
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